Services:

Value & Access

Our team of Value & Access experts work across functions to leverage locally-nuanced, but comprehensively global, value-based pricing and market access strategies.

Home / Services / Value & Access

The pharma landscape has become more nuanced and complex, so the need for a robust value and access strategy is more important than ever. Trinity works across all phases of development, from pre-clinical prioritization to final pricing assessment and value communication to support a product’s access and commercial success.

Global Expertise

  • Asia Pacific

    Trinity’s expertise spans many different healthcare systems and payer landscapes within the Asia Pacific region. We have a deep knowledge of the nuanced differences within each market of the region and understand when it is beneficial or necessary to gather insights from stakeholders beyond payers and physicians to answer our client’s questions.

    Questions Our Clients Ask
    • What is the local healthcare environment and payer landscape like in market X?
    • What are the opportunities and challenges in the public and private sectors of market X?
    • What pricing methodology will be employed in Japan? What would be the impact of any cost-effectiveness analysis?
    • What provisions exist for orphan therapies and how can I best access them?
    • What does it take to shift my specialty product from an out of pocket strategy to a reimbursed approach?
    • What are the key learnings from analogs with launch success in this market?
    Local Language Capabilities

    Mandarin, Cantonese, Japanese, Korean & Indonesian

    Specialized Markets

    China, Japan, Korea, Taiwan, Singapore & Indonesia

    The Trinity Difference
    • We partner with clients to design tailored in-depth research methodologies that help to track market dynamics and the most recent pricing and access changes in a country.
    • We are skilled at solving nuanced issues in a fast-paced landscape. We utilize insights from industry experts to provide insightful recommendations.
  • Central and Eastern Europe

    Trinity delivers unique insights for the Central and Eastern Europe region that are locally accurate with deliverable quality that matches that seen for Western Europe and the US.

    Questions Our Clients Ask
    • Which funding routes are available across national, regional, and local channels?
    • How can we provide access and support patients not covered under healthcare budget?
    • How influential are third parties in reimbursement decisions (e.g. KOLs, patient associations
    • What would be an appropriate price point for PRODUCT X for it to be successful in obtaining reimbursement listing?
    • Would PRODUCT X have an advantage if it is manufactured / packaged domestically? What are opportunities for technology transfers to ensure a certain market share?
    Local Language Capabilities

    Russian & Polish

    Specialized Markets

    Russia, Poland, Czech Republic, Hungary, Bulgaria, Greece, Romania, Ukraine, Kazakhstan, Belarus

    The Trinity Difference
    • We have a comprehensive knowledge of local market dynamics for stakeholders within key markets in Eastern Europe and the CIS region.
    • We address nuanced questions on CEE-relates issues coming from regional and global clients on topics such as: IRP dynamics implications, interpretation of policy update and overview of the reimbursement landscape.
  • EUROPE, UK, AND CANADA

    We work with clients to meet the unique local needs of health systems across Europe (EU), UK and Canada while ensuring the integrity of both their regional and commercial access objectives. We have the global expertise to engage with business unit leaders on cross-market strategy, and our in-house local expertise and experience is paired with a strong network of healthcare decision-makers across the region.

    Questions Our Clients Ask
    • What is the pricing, access, and/or commercial opportunity for my asset in the EU?
    • How can we develop a value proposition that meets the needs of customers across markets and roles?
    • Based on our pivotal trial, what HTA outcomes are likely in the EU, and how can we improve this potential? How will positive or negative outcomes in one EU market influence the others?
    • How will follow-on indications impact our pricing and access, and what does this mean for our launch and submission strategy?
    Local Language Capabilities

    German, French, Spanish, Portuguese, Italian & Dutch

    Specialized Markets

    Germany, Great Britain, France, Italy, Spain, Sweden, NetherlandsCanada 

    The Trinity Difference
    • We have active collaborations with thought leaders for conference publications and presentations
    • We run a host of different virtual and face-to-face research that is customized depending on project type and dynamics so that our clients can gain insights firsthand. Methodologies include: online quant and qual surveys, dyads & tryads, internal workshops, webinars, working sessions, mock-negotiation workshops, 1:1 telephone discussions, unblinded ad-boards, and focus groups
    • Our relationships are personal and critical to receive up-to-date and informed perspectives
    • We have experience facilitating logistically complex affiliate strategy and training workshops and meetings with upwards of 100+ cross-functional participants
  • Latin America

    Our LatAm experts have deep regional expertise across therapeutic areas. The most notable project work to date is concerned with oncology, inflammatory diseases, rare diseases, multiple sclerosis and respiratory diseases.

    Questions Our Clients Ask
    • What are the market segments with the highest opportunity at launch, and how do we unlock them?
    • How can we influence local policy to help shape the P&MA landscape?
    • What is the trade-off between price and volume by pursuing specific sub-populations and market segments?
    • How can we prepare our local teams to effectively deliver value stories that resonate with their local stakeholders?
    Local Language Capabilities

    Spanish & Brazilian Portuguese

    Specialized Markets

    Brazil, Argentina, Colombia, Mexico, Panama, Dominican Republic

    The Trinity Difference
    • Our dedicated team of LatAm experts truly understand the complexities or each major market within the region. We strive to ensure our insights are delivered with complete accuracy and by consultants who speak the local languages of our network.
    • We address nuanced questions for local teams and ensure our deliverable quality that matches that seen for Western Europe and the US.
  • USA

    Trinity has extensive experience across differential payer stakeholders in the US – MCOs, PBMs, MACs, Practice Managers, Pathway Vendors, etc. With a constantly evolving pricing and access landscape, we must always have a pulse on the changing policy landscape and be ready to pivot our strategies accordingly. We work with clients across the product lifecycle starting with early phase “gut checks” to thorough price analyses and contracting strategies to ensure an optimized launch.

    Questions Our Clients Ask
    • How restrictive will the payer prior authorization be for our product?
    • What is our value-based price?
    • How will access change for the follow-on indication?
    • What will payer management look like in disease state X in the next five years?
    • What are the specific access hurdles the practice is experiencing with our product?
    Specialized Markets

    USA

    The Trinity Difference
    • We have vast experience supporting the pricing and access launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, differential pricing across indications, DRG-based reimbursement and NTAP considerations, etc.)
    • We have extensive experience with high profile dynamics such as: cell and gene therapy, alternative payment models, NGS testing, and portfolio contracting

Knowledge Hubs

Cell and Gene Therapy

Cell and Gene Therapy

Cell and gene therapies represent a fundamental therapeutic revolution. Our expert team focuses on assessing the unique opportunities and challenges associated with the emerging class of novel treatments. With a lens towards identifying key value, access and pricing dynamics, we can determine the influence these innovative treatments will have when entering the cell and gene therapy market.

Learn More

Portfolio Optimization

Portfolio Optimization

We provide comprehensive pharma portfolio strategy insights and portfolio lifestyle management expertise that account for both commercial and market access issues. These are developed with local expert knowledge as the foundation to the research process.

Learn More

Value Strategy

Value Strategy

We seek insights and challenge internal thinking to develop impactful value stories for regional and global pharmaceutical clients. A winning value proposition must evolve over the course of a product’s life cycle and we recognize the challenges involved throughout every stage of the value story development.

Learn More

Early Value, Access & Pricing & Commercial Planning

Early Value, Access & Pricing & Commercial Planning

We work to understand ways in which Value, Access, and Pricing (VAP) and Commercial Planning (CP) intersect and influence each other in the early pipeline stages. Our VAP and CP team has robust capabilities which sit across both functions, helping us to provide specialized pharmaceutical positioning, market access, and pipeline strategy.

Learn More

Latest Value & Access Intelligence

Blog

CAR Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare […]

 Read More

Blog

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake. Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization […]

 Read More

Blog

2019 NRDL: Insights for Future Pricing Negotiations in China

China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited […]

 Read More

Meet Our Value & Access Experts

If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.